What's in store for Indian pharma? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

What's in store for Indian pharma?

Oct 20, 2009

The overall growth for the Indian pharma sector has been mixed in the last few quarters. While there were some factors that impacted the entire sector as a whole, there were certain developments which were company specific. Nevertheless they were instrumental in determining the performance of the companies. Many domestic pharma companies, especially the ones who had taken on foreign debt on their books, had a tough time in the last few quarters as the rupee depreciated sharply against the US dollar. This compelled them to report huge forex losses which dented profitability. Companies such as Ranbaxy and Sun Pharma ran into trouble with the US FDA as their manufacturing plants were found not to be complying with the quality standards of the US FDA. This adversely impacted their sales from the US. The global crisis also impacted the business of the pharma companies to a certain extent especially in the semi regulated markets of Russia and the CIS as the latter's currencies got significantly devalued. As a result many companies were compelled to focus more on receivables in these markets even if that meant foregoing some sales.

The September quarter results season for the pharma sector will begin this week and they are expected to be much better than what was witnessed in the latter half of FY09. The magnitude of forex losses is not likely to be pronounced this quarter given that the Indian unit has appreciated against the US dollar. While most of the companies are likely to post decent revenues from the domestic market, the exports performance is expected to be a mixed bag. Revenues from the emerging markets are likely to grow at a robust pace but sales are likely to be relatively lower in the developed markets of US and Europe. For those plagued by US FDA issues, growth in sales from the US market is not likely to be much.

MNC pharma companies are also expected to post better results as compared to what they did in the past two years. It must be noted that the performance of MNC pharma was hampered in FY09 due to trade issues, sale of non-core assets and rising input costs. But this scenario has changed as was evinced in the last two quarters and the top companies have begun to post decent growth in sales. Infact, dabbling in generics has emerged as an area of interest to these MNCs and some such as Pfizer India have already launched a couple of generic products in the domestic market to bolster performance.

Having said that, looking at only quarterly numbers should not form the basis of investing in stocks, including those in the pharma sector. Infact, investment decisions have to be based from a 2-3 year perspective. In this regard, the long term prospects of the pharma sector look intact as the fundamentals in terms of governments across the world veering towards low cost generics have not changed. However, mirroring the Indian stockmarkets, pharma stocks have also rallied considerably over the past few months. Hence, we advice investors to adopt a stock specific approach while investing in the sector.

Equitymaster requests your view! Post a comment on "What's in store for Indian pharma?". Click here!


More Views on News

IDFC Mutual Fund Starts Campaign 'SIFI'. Should Buy Into the Idea? (Outside View)

Sep 23, 2020

IDFC Mutual Fund is taking the road less travelled and hence started a campaign SIFI (SIP in Fixed Income) to promote the concept of SIP for its debt funds investors.

My View on the IPO Market (Fast Profits Daily)

Sep 23, 2020

In this video, I'll share with you my thoughts on the recent spate of IPOs and what it means for the market.

I Believe These Stocks Will Deliver the Most Outsized Returns in 2021 and Beyond (Profit Hunter)

Sep 23, 2020

Rules of the racetrack can help you bag the biggest gainers of the coming decade.

An Important Hurricane Update for Energy Traders (Fast Profits Daily)

Sep 22, 2020

In this video, I'll show you how the extended hurricane season in the US will affect traders in crude oil and natural gas.

Mutual Fund Investors Will Now Be Allotted Units Based on NAV of the Day AMCs Receive Funds (Outside View)

Sep 22, 2020

PersonalFN explains how SEBI's new circular on mutual funds impact investors.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 23, 2020 (Close)